Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

Novartis India

Novartis Italia

Novartis Nederland

Chinook Therapeutics, a Novartis Company

Novartis España

Novartis Magyarország

Novartis Israel

Novartis Slovakia

Novartis Czech Republic

Novartis Danmark

Novartis Brasil

Novartis Portugal

Novartis Gulf | نوفارتس الخليج

Novartis, Australia & New Zealand

Novartis in Slovenia

Novartis Norge

Novartis Finland

Novartis Argentina

Novartis Colombia

Novartis Sverige

Novartis Belux

Novartis Singapore

Novartis Ireland 

Novartis Deutschland

Novartis Gene Therapies

Novartis România

Novartis México

Novartis Science

Novartis Medical

Novartis US Medical

Novartis Canada

Novartis US

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. 

Find out more at https://www.novartis.com 

See our community guidelines: https://go.novartis.social/3Nboxki

Molecular Partners

SomaLogic

Aduro BioTech

Arcus Biosciences

Roche

Science 37

BiolineRx

C4 Therapeutics

Ayala Pharmaceuticals

Semma Therapeutics

Caribou Biosciences

Pear Therapeutics

Poseida Therapeutics

Gamida Cell

Homology Medicines

Rani Therapeutics

Intellia Therapeutics

Bill & Melinda Gates Foundation

Novartis

Patients and caregivers know better than anyone what it means to live with a disease every day. 

By working with patient organizations, we systematically build patients’ perspectives into key decisions through a medicine’s life cycle. 

Six years ago, Novartis became the first Pharma company to publish a Commitment to Patients and Caregivers – our promise to embed the patient perspective in our journey to reimagine medicine. 

Every year, we publish our Factsheet to share our progress in numbers made against our commitment. From involving the perspective of those living with a condition at an early stage to co-creating clinical endpoints, we are applying this approach to more than 100 investigational medicines at different stages of the life cycle. These include potential treatments for chronic myeloid leukemia (CML), psoriasis, hidradenitis suppurativa, and Sjögren’s syndrome. 

With our Commitment to Patients and Caregivers, we continue to prioritize the outcomes that matter most to patients to bring forward innovative medicines that create value for patients and health systems. https://lnkd.in/gyRRQchF


In a world where as many as half of us will receive a cancer diagnosis, the words we use to talk about it matter.

When it comes to the language of cancer, Novartis is putting people living with cancer at the center of the discussion. Through our partnership with a multidisciplinary steering committee of experts and input from a transatlantic exploratory survey of people living with cancer, their caregivers and physicians in the US and the UK, we are exploring the effects of the language used when referring to cancer. 

Find out more at http://ms.spr.ly/6044iFJZM

#WorldCancerDay #MyCancerMyWords

Unsurprisingly, negative words are among the first that come to mind for most people living with cancer. But why does this matter?

Hear from Dr Simon De Deyne, Cognitive Scientist at the University of Melbourne, and one of the expert advisors researching the ways that we talk about cancer. 

Explore how 2,000 people living and working with cancer responded to an exploratory survey in the US and UK and why their answers matter at http://ms.spr.ly/6047iFJuD

#MyCancerMyWords
#CancerAwareness 
#CancerCommunity
#livingwithcancer

Words matter. The language used in cancer can have lasting effects on people living with cancer.

Listen to Claire Saxton, Executive Vice President for the Cancer Support Community, and member of the My Cancer. My Words. Steering Committee, on why it’s important that people living with cancer, caregivers and health care professionals openly talk about the preferences they have when it comes to the words used to describe cancer. 

Find out more about our work at http://ms.spr.ly/6041iFJHc

#WorldCancerDay
#MyCancerMyWords
#CancerAwareness 
#CancerCommunity
#livingwithcancer

In 2023, we entered our new era as an innovative medicines company, working every day to restore possibilities for the millions of people living with major diseases around the world.
 
From 280+ million people reached with our medicines to over USD 8 billion invested in research and development.
 
Discover highlights from the year and learn more about how we are delivering on our purpose to reimagine medicine in our Novartis in Society Integrated Report 2023: https://lnkd.in/gJVzjtKi

SIX:NOVN

Novartis

Last Close

101.92

30/08 15:31

Market Cap

193.82B

Beta: 0.46

Volume Today

4.01M

Avg: 4.71M

PE Ratio

14.33

PFCF: 18.41

Dividend Yield

3.08%

Payout:48.86%